Breakdown of debtors, Realkredit Danmark A/S
| To Nasdaq Copenhagen A/S | Executive Board Lersø Parkallé 100 DK-2100 København Ø www.rd.dk Telephone +45 7012 5300 Telefax +45 4514 9622 25 November 2022 |
Company Announcement No 106/2022
Breakdown of debtors, Realkredit Danmark A/S
Pursuant to §24 of the Capital Markets Act, Realkredit Danmark A/S hereby publishes breakdown of debtors as at Friday 18 November 2022. Please find the data in the attached file.
The information will also be available on www.rd.dk.
Yours sincerely
The Executive Board
Any additional questions should be addressed to Hella Gebhardt Rønnebæk, Chief Analyst, phone +45 4513 2068.
Attachments
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
ING announces share buyback programme of up to €2.5 billion2.5.2024 07:03:00 CEST | Press release
ING announces share buyback programme of up to €2.5 billion ING announced today a share buyback programme under which it plans to repurchase ordinary shares of ING Groep N.V., for a maximum total amount of €2.5 billion. The purpose of the share buyback programme is to converge our CET1 ratio towards our target of around 12.5%. ING Group’s CET1 ratio was 14.8% at the end of the first quarter of 2024, which is well above the prevailing CET1 ratio requirement of 10.94%. The share buyback programme will have an impact of approximately 77 bps on our CET1 ratio. The programme will commence on 2 May 2024 and is expected to end no later than 29 October 2024. The ECB has approved the programme, which will be executed in compliance with the Market Abuse Regulation and within the limitations of the existing authority to acquire a maximum of 20% of the issued shares as granted by the general meeting of shareholders on 22 April 2024. ING has entered a non-discretionary arrangement with a financial
CEX.IO Launches Mastercard-branded Crypto Debit Card2.5.2024 07:00:00 CEST | Press release
The new product enables registered users in the EEA to make everyday payments with their crypto holdings, and integrates seamlessly with CEX.IO App. VILNIUS, May 02, 2024 (GLOBE NEWSWIRE) -- CEX.IO, a global ecosystem working to bridge the worlds of crypto and traditional finance, announces the debut of CEX.IO Card, a debit card that empowers users to seamlessly spend their crypto assets on everyday purchases. This innovative product marks a pivotal step forward in CEX.IO’s mission to simplify crypto adoption, and bring the benefits of decentralized finance to the masses. The CEX.IO Card seamlessly integrates into users’ existing spending habits, allowing them to effortlessly make purchases with millions of merchants who accept Mastercard, in over 150 countries. Users can fund their cards via a variety of accessible methods, including bank transfers, as well as fiat and crypto deposits. In addition, they may set ranked priorities for their preferred methods, ensuring they always have a
ONWARD® Medical Convocation of the 2024 Annual General Meeting of Shareholders and Proposed Resolutions2.5.2024 07:00:00 CEST | Press release
EINDHOVEN, the Netherlands, May 02, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), a medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today has convened the 2024 Annual General Meeting of Shareholders (AGM), which will include consideration of the resolutions to be submitted for adoption at the AGM, which will be held in Amsterdam, the Netherlands, on June 13, 2024. The resolutions, proposed by the Board, to be submitted for adoption at the AGM, are as follows: Adoption of the Company’s statutory annual accounts for the financial year ended December 31, 2023, prepared in accordance with International Financial Reporting Standards (IFRS-EU). The 2023 statutory accounts were filed with the Netherlands Authority for the Financial Markets (AFM) on April 25, 2024, and are posted on the Company’s website (www.ir.onwd.com) and the AFM's website (afm.nl). Imp
Biotalys Starts Field Trials for Second Biofungicide2.5.2024 07:00:00 CEST | Press release
Ghent, BELGIUM, May 02, 2024 (GLOBE NEWSWIRE) -- Biotalys (Euronext: BTLS) an Agricultural Technology (AgTech) company developing protein-based biocontrols for sustainable crop protection, today announced the initiation of field trials for BioFun-6, the company’s second biofungicide program under development on its AGROBODY technology platform. Kevin Helash, Chief Executive Officer of Biotalys,commented: “Moving BioFun-6 into the field is another important milestone for Biotalys, demonstrating our ability to advance a series of protein-based bioactive ingredients on our platform in concert. As our first product candidate, EVOCA™, progresses through the needed regulatory process and its commercial version EVOCA NG enters its final development stage with our partner Novonesis, we will continue to build our strong pipeline of biofungicides and bioinsecticides to help growers in their transition towards more sustainable practices.” BioFun-6 is a biofungicide targeting botrytis, powdery mil
Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations2.5.2024 07:00:00 CEST | Press release
Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations New real-world evidence shows Beyfortus (nirsevimab) substantially reduced RSV lower respiratory tract disease and hospitalizations in infants during the 2023-2024 RSV season, versus no intervention1-6Results add to the consistent high efficacy of Beyfortus against medically attended RSV lower respiratory tract disease, shown in the pivotal clinical studies and the outcomes from HARMONIE, a phase 3b clinical study conducted in close to real-life conditions7-10 Paris, May 2, 2024. Beyfortus reduced respiratory syncytial virus (RSV) hospitalizations by 82% (95% CI: 65.6 to 90.2) in infants under 6 months of age, compared to infants who received no RSV intervention, according to the interim results of an ongoing study published in The Lancet. These results, from the first RSV season after Beyfortus’ introduction, are part of the three-year NIRSE-GAL study conducted in Galicia, Spain un